<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; mega</title>
	<atom:link href="http://www.tapanray.in/tag/mega/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Pharmaceutical Brand Building in a Changing Scenario: Thinking Outside the Box</title>
		<link>http://www.tapanray.in/pharmaceutical-brand-building-in-a-changing-scenario-thinking-outside-the-box/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharmaceutical-brand-building-in-a-changing-scenario-thinking-outside-the-box</link>
		<comments>http://www.tapanray.in/pharmaceutical-brand-building-in-a-changing-scenario-thinking-outside-the-box/#comments</comments>
		<pubDate>Mon, 18 Feb 2013 00:00:24 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[advair]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[building]]></category>
		<category><![CDATA[changing]]></category>
		<category><![CDATA[emotional]]></category>
		<category><![CDATA[equity]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Lipitor]]></category>
		<category><![CDATA[mega]]></category>
		<category><![CDATA[nexium]]></category>
		<category><![CDATA[NovoNordisk]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[paradigm]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[shift]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=1405</guid>
		<description><![CDATA[In this article, I shall explore unconventional ways of “Building sustainable Pharmaceutical Brands” thinking  outside the box, after quickly taking you through the “Challenges of Change” in the evolving dynamics of  the Indian branded generic market. A paradigm shift has &#8230; <a href="http://www.tapanray.in/pharmaceutical-brand-building-in-a-changing-scenario-thinking-outside-the-box/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharmaceutical-brand-building-in-a-changing-scenario-thinking-outside-the-box/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biologic Medicine: Ushers in a different &#8216;Mega Race&#8217; for inorganic growth</title>
		<link>http://www.tapanray.in/biologic-medicine-ushers-in-a-different-mega-race-for-inorganic-growth/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=biologic-medicine-ushers-in-a-different-mega-race-for-inorganic-growth</link>
		<comments>http://www.tapanray.in/biologic-medicine-ushers-in-a-different-mega-race-for-inorganic-growth/#comments</comments>
		<pubDate>Mon, 02 May 2011 00:30:50 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biologicals]]></category>
		<category><![CDATA[biosimilars]]></category>
		<category><![CDATA[different]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[inorganic]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[mega]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Race]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Ushers]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=265</guid>
		<description><![CDATA[During the last several years the success of biologics compared to conventional small-molecule drugs to meet the unmet needs of patients, is gradually but surely changing the area of focus of pharmaceutical R&#38;D altogether, making the biotech companies interesting targets &#8230; <a href="http://www.tapanray.in/biologic-medicine-ushers-in-a-different-mega-race-for-inorganic-growth/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/biologic-medicine-ushers-in-a-different-mega-race-for-inorganic-growth/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Global Pharmaceutical Industry: Capturing the micro-trends, having potential to become future mega-trends.</title>
		<link>http://www.tapanray.in/global-pharmaceutical-industry-capturing-the-micro-trends-having-potential-to-become-future-mega-trends/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=global-pharmaceutical-industry-capturing-the-micro-trends-having-potential-to-become-future-mega-trends</link>
		<comments>http://www.tapanray.in/global-pharmaceutical-industry-capturing-the-micro-trends-having-potential-to-become-future-mega-trends/#comments</comments>
		<pubDate>Wed, 25 Mar 2009 03:30:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Capturing]]></category>
		<category><![CDATA[cliff]]></category>
		<category><![CDATA[expiry]]></category>
		<category><![CDATA[future]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[having]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[mega]]></category>
		<category><![CDATA[micro]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[potential]]></category>
		<category><![CDATA[productivity]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to become]]></category>
		<category><![CDATA[trends]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=932</guid>
		<description><![CDATA[The situation:Almost the entire developed world is reeling under recession&#8230; Slowed down business growth&#8230; Gradual drying up of research pipeline&#8230; Skyrocketing R&#38;D cost&#8230; Pressure on product price &#8230;Market capitalization going south&#8230; Cut throat market competition&#8230; Depressed business sentiments&#8230;Past M&#38;As are &#8230; <a href="http://www.tapanray.in/global-pharmaceutical-industry-capturing-the-micro-trends-having-potential-to-become-future-mega-trends/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/global-pharmaceutical-industry-capturing-the-micro-trends-having-potential-to-become-future-mega-trends/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
